Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.
2.

Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.

Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Drugs Dermatol. 2018 Oct 1;17(10):1062-1069.

PMID:
30365586
3.

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.

Langley RG, Armstrong AW, Lebwohl MG, Blauvelt A, Hsu S, Tyring S, Rastogi S, Pillai R, Israel R.

Br J Dermatol. 2018 Oct 17. doi: 10.1111/bjd.17318. [Epub ahead of print]

PMID:
30328108
4.

Long-term safety results from a Phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) lotion in moderate-to-severe plaque psoriasis.

Lebwohl MG, Sugarman JL, Gold LS, Pariser DM, Lin T, Pillai R, Martin G, Harris S, Israel R.

J Am Acad Dermatol. 2018 Sep 15. pii: S0190-9622(18)32569-6. doi: 10.1016/j.jaad.2018.09.002. [Epub ahead of print] No abstract available.

PMID:
30227193
5.

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.

Webster LR, Israel RJ.

J Pain Res. 2018 Aug 13;11:1503-1510. doi: 10.2147/JPR.S160488. eCollection 2018.

6.

Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.

Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R.

J Drugs Dermatol. 2018 Aug 1;17(8):855-861.

PMID:
30124724
7.

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.

Fodor AA, Pimentel M, Chey WD, Lembo A, Golden PL, Israel RJ, Carroll IM.

Gut Microbes. 2018 Apr 30:1-28. doi: 10.1080/19490976.2018.1460013. [Epub ahead of print]

PMID:
29708822
8.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.

Gold LS, Lebwohl MG, Sugarman JL, Pariser DM, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T.

J Am Acad Dermatol. 2018 Aug;79(2):287-293. doi: 10.1016/j.jaad.2018.03.040. Epub 2018 Apr 1.

9.

Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.

Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R.

J Eur Acad Dermatol Venereol. 2018 Mar 6. doi: 10.1111/jdv.14913. [Epub ahead of print]

PMID:
29512200
10.

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.

Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ.

Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23.

PMID:
29488226
11.

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.

Lebwohl MG, Papp KA, Marangell LB, Koo J, Blauvelt A, Gooderham M, Wu JJ, Rastogi S, Harris S, Pillai R, Israel RJ.

J Am Acad Dermatol. 2018 Jan;78(1):81-89.e5. doi: 10.1016/j.jaad.2017.08.024. Epub 2017 Oct 3. Review.

PMID:
28985956
12.

Erratum to: Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P.

Dig Dis Sci. 2017 Oct;62(10):2945. doi: 10.1007/s10620-017-4729-1. No abstract available.

PMID:
28884456
13.
14.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3).

Blauvelt A, Papp KA, Lebwohl MG, Green LJ, Hsu S, Bhatt V, Rastogi S, Pillai R, Israel R.

J Am Acad Dermatol. 2017 Aug;77(2):372-374. doi: 10.1016/j.jaad.2017.03.026. No abstract available.

PMID:
28711089
15.

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P.

Dig Dis Sci. 2017 Sep;62(9):2455-2463. doi: 10.1007/s10620-017-4598-7. Epub 2017 Jun 6. Erratum in: Dig Dis Sci. 2017 Sep 7;:.

16.

Corrigendum to "Untangling the relatedness among correlations, Part I: Nonparametric approaches to inter-subject correlation analysis at the group level" [Neuroimage (in press)].

Chen G, Shin YW, Taylor PA, Glen DR, Reynolds RC, Israel RB, Cox RW.

Neuroimage. 2017 Jan 15;145(Pt A):130-132. doi: 10.1016/j.neuroimage.2016.10.021. Epub 2016 Oct 28. No abstract available.

17.

Randomized, Double-Blind Trial of Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain.

Rauck R, Slatkin NE, Stambler N, Harper JR, Israel RJ.

Pain Pract. 2017 Jul;17(6):820-828. doi: 10.1111/papr.12535. Epub 2017 Feb 10.

PMID:
27860208
18.

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin.

DuPont HL, Wolf RA, Israel RJ, Pimentel M.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e02165-16. doi: 10.1128/AAC.02165-16. Print 2017 Jan. No abstract available.

19.

Untangling the relatedness among correlations, part I: Nonparametric approaches to inter-subject correlation analysis at the group level.

Chen G, Shin YW, Taylor PA, Glen DR, Reynolds RC, Israel RB, Cox RW.

Neuroimage. 2016 Nov 15;142:248-259. doi: 10.1016/j.neuroimage.2016.05.023. Epub 2016 May 17. Erratum in: Neuroimage. 2017 Jan 15;145(Pt A):130-132.

20.

Combining Face-to-face Therapy with Computerized Techniques: A therapists' Attitudes Survey.

Shalom JG, Israel R, Shalom N.

Stud Health Technol Inform. 2015;219:69-74.

PMID:
26799882
21.

An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas.

Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, Clarke-Pearson D, Goff B, Bristow R, Taylor HS, Farias-Eisner R, Fader AN, Maxwell GL, Goodwin SC, Love S, Gibbons WE, Foshag LJ, Leppert PC, Norsigian J, Nager CW, Johnson T, Guzick DS, As-Sanie S, Paulson RJ, Farquhar C, Bradley L, Scheib SA, Bilchik AJ, Rice LW, Dionne C, Jacoby A, Ascher-Walsh C, Kilpatrick SJ, Adamson GD, Siedhoff M, Israel R, Paraiso MF, Frumovitz MM, Lurain JR, Al-Hendy A, Benrubi GI, Raman SS, Kho RM, Anderson TL, Reynolds RK, DeLancey J.

J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):303-8. doi: 10.1016/j.jmig.2015.12.012. Epub 2016 Jan 8. No abstract available.

PMID:
26773577
22.

Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension.

Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP.

J Palliat Med. 2015 Jul;18(7):593-600. doi: 10.1089/jpm.2014.0362. Epub 2015 May 14.

23.

Antibody-drug conjugates targeting prostate-specific membrane antigen.

Olson WC, Israel RJ.

Front Biosci (Landmark Ed). 2014 Jan 1;19:12-33. Review.

PMID:
24389170
24.

Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.

Chao T, Ladd JJ, Qiu J, Johnson MM, Israel R, Chin A, Wang H, Prentice RL, Feng Z, Disis ML, Hanash S.

Proteomics Clin Appl. 2013 Jun;7(5-6):327-36. doi: 10.1002/prca.201200058. Epub 2013 May 10.

25.

Randomized placebo-controlled study of intravenous methylnaltrexone in postoperative ileus.

Viscusi ER, Rathmell JP, Fichera A, Binderow SR, Israel RJ, Galasso FL, Penenberg D, Gan TJ.

J Drug Assess. 2013 Aug 27;2(1):127-34. doi: 10.3109/21556660.2013.838169. eCollection 2013.

26.

Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women.

Ladd JJ, Chao T, Johnson MM, Qiu J, Chin A, Israel R, Pitteri SJ, Mao J, Wu M, Amon LM, McIntosh M, Li C, Prentice R, Disis N, Hanash S.

Cancer Res. 2013 Mar 1;73(5):1502-13. doi: 10.1158/0008-5472.CAN-12-2560. Epub 2012 Dec 26.

27.

A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.

Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP, Israel R, Scher HI, Morris S.

Vaccine. 2013 Jan 30;31(6):943-9. doi: 10.1016/j.vaccine.2012.11.096. Epub 2012 Dec 13.

PMID:
23246260
28.

LASSA: Emotion Detection via Information Fusion.

Yu N, K├╝bler S, Herring J, Hsu YY, Israel R, Smiley C.

Biomed Inform Insights. 2012;5(Suppl. 1):71-6. doi: 10.4137/BII.S8949. Epub 2012 Jan 30.

29.

Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials.

Slatkin NE, Lynn R, Su C, Wang W, Israel RJ.

J Pain Symptom Manage. 2011 Nov;42(5):754-60. doi: 10.1016/j.jpainsymman.2011.02.015.

PMID:
22045373
30.

Interventional cardiology in 2011- a look back.

Schatz RA, Israel RL.

Am Heart Hosp J. 2011 Summer;9(1):E11-4. No abstract available.

PMID:
21823069
31.

Is pocket mobile echocardiography the next-generation stethoscope? A cross-sectional comparison of rapidly acquired images with standard transthoracic echocardiography.

Liebo MJ, Israel RL, Lillie EO, Smith MR, Rubenson DS, Topol EJ.

Ann Intern Med. 2011 Jul 5;155(1):33-8. doi: 10.7326/0003-4819-155-1-201107050-00005.

32.

Methylnaltrexone for opioid-induced constipation in patients with advanced illness: a 3-month open-label treatment extension study.

Lipman AG, Karver S, Cooney GA, Stambler N, Israel RJ.

J Pain Palliat Care Pharmacother. 2011;25(2):136-45. doi: 10.3109/15360288.2011.573531.

PMID:
21657861
33.

Methylnaltrexone potentiates body weight and fat reduction with leptin.

Yuan CS, Sun S, Attele A, Wang CZ, Tong R, Israel RJ.

J Opioid Manag. 2009 Nov-Dec;5(6):373-8.

PMID:
20073411
34.

A long-duration (118-day) backpacking trip (2669 km) normalizes lipids without medication: a case study.

Devoe D, Israel RG, Lipsey T, Voyles W.

Wilderness Environ Med. 2009 Winter;20(4):347-52. doi: 10.1580/1080-6032-020.004.0347.

PMID:
20030443
35.

Case report of human immunodeficiency virus infection, Hodgkin lymphoma, and pregnancy.

Israel R, Dorer R, Aboulafia DM.

Am J Med Sci. 2010 Feb;339(2):185-7. doi: 10.1097/MAJ.0b013e3181bcc633.

PMID:
20019583
36.

A retrospective analysis of AIDS-associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3).

Mani D, Neil N, Israel R, Aboulafia DM.

J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct;8(5):279-85. doi: 10.1177/1545109709341852. Epub 2009 Aug 31.

PMID:
19721098
37.

Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness.

Chamberlain BH, Cross K, Winston JL, Thomas J, Wang W, Su C, Israel RJ.

J Pain Symptom Manage. 2009 Nov;38(5):683-90. doi: 10.1016/j.jpainsymman.2009.02.234. Epub 2009 Aug 26.

PMID:
19713070
38.

Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model.

Yuan CS, Wang CZ, Mehendale SR, Aung HH, Foo A, Israel RJ.

AIDS Res Ther. 2009 Aug 21;6:19. doi: 10.1186/1742-6405-6-19.

39.

Effects of anesthetics on cancer recurrence.

Moss J, Israel RJ.

J Clin Oncol. 2009 Sep 1;27(25):e89; author reply e90. doi: 10.1200/JCO.2009.23.7651. Epub 2009 Aug 3. No abstract available.

PMID:
19652045
40.

Cardiorespiratory fitness and the metabolic syndrome in firefighters.

Donovan R, Nelson T, Peel J, Lipsey T, Voyles W, Israel RG.

Occup Med (Lond). 2009 Oct;59(7):487-92. doi: 10.1093/occmed/kqp095. Epub 2009 Jul 3.

PMID:
19578075
41.

Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients.

Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, Zhukovsky DS, Stephenson R, Portenoy R, Stambler N, Israel R.

J Support Oncol. 2009 Jan-Feb;7(1):39-46.

PMID:
19278178
42.

Fracture of an alumina femoral head used in ceramic-on-ceramic total hip arthroplasty.

Rhoads DP, Baker KC, Israel R, Greene PW.

J Arthroplasty. 2008 Dec;23(8):1239.e25-30. doi: 10.1016/j.arth.2007.09.017. Epub 2008 Apr 11.

PMID:
18534489
43.

Methylnaltrexone for opioid-induced constipation in advanced illness.

Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ.

N Engl J Med. 2008 May 29;358(22):2332-43. doi: 10.1056/NEJMoa0707377.

44.

Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study.

Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, Von Gunten CF, Israel RJ.

J Pain Symptom Manage. 2008 May;35(5):458-68. doi: 10.1016/j.jpainsymman.2007.12.005.

PMID:
18440447
46.

Early failure of bioabsorbable anterior cervical fusion plates: case report and failure analysis.

Brkaric M, Baker KC, Israel R, Harding T, Montgomery DM, Herkowitz HN.

J Spinal Disord Tech. 2007 May;20(3):248-54.

PMID:
17473648
47.

Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone.

Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R.

Clin Pharmacol Ther. 2007 Jul;82(1):48-53. Epub 2007 Mar 28.

PMID:
17392726
48.

Effect of polyethylene pretreatments on the biomimetic deposition and adhesion of calcium phosphate films.

Baker KC, Drelich J, Miskioglu I, Israel R, Herkowitz HN.

Acta Biomater. 2007 May;3(3):391-401. Epub 2006 Oct 31.

PMID:
17079198
49.

A family-based approach to preventing excessive weight gain.

Rodearmel SJ, Wyatt HR, Barry MJ, Dong F, Pan D, Israel RG, Cho SS, McBurney MI, Hill JO.

Obesity (Silver Spring). 2006 Aug;14(8):1392-401.

50.

Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects.

Yuan CS, Israel RJ.

Expert Opin Investig Drugs. 2006 May;15(5):541-52. Review.

PMID:
16634692

Supplemental Content

Loading ...
Support Center